Form 4: Hinge Health CEO Sells Shares Under 10b5-1 Plan

Hinge Health CEO Daniel Antonio Perez sold 166,665 shares of Class A Common Stock for approximately $40.26 per share under a pre-arranged trading plan.

Summary

• Daniel Antonio Perez, CEO & Co-Founder, Director, and 10% Owner of Hinge Health, Inc. (HNGE), reported transactions on February 12, 2026.
• Perez converted 166,665 shares of Class B Common Stock into Class A Common Stock.
• Concurrently, Perez sold 166,665 shares of Class A Common Stock at a weighted average price of $40.2635 per share.
• The sales were executed under a Rule 10b5-1 trading plan established on September 11, 2025.
• Following these transactions, Perez directly holds 0 Class A Common Stock and 9,488,845 Class B Common Stock, which are convertible into Class A shares.
• Perez's spouse indirectly holds 35,470 Class A Common Stock and 515,705 Class B Common Stock.
• The reported Class B Common Stock holdings exclude 4,721,252 performance stock units held by Perez.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale reduces direct equity, its execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic timing, suggesting a routine liquidity or diversification event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent transaction rather than an immediate reaction to market conditions.
• The sale price of $40.2635 per share is within a range of $40.00 to $40.88, indicating a relatively strong market price for the transaction.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under Rule 10b5-1 plans, are common occurrences in the public markets. These plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information, providing a degree of transparency to the market.

Comparison to Industry Standards

• StockSavvy.ai observes that the sale of 166,665 shares by a CEO, while significant in volume, represents a small fraction of Daniel Antonio Perez's total beneficial ownership, especially considering his substantial holdings of Class B Common Stock and performance stock units. This is a standard practice for executives managing personal liquidity and diversification, similar to sales by CEOs at companies like Microsoft (Satya Nadella) or Apple (Tim Cook) who periodically sell shares under 10b5-1 plans without necessarily signaling a negative outlook for their respective companies.

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted in various ways, but the 10b5-1 plan context suggests it's not a signal of lack of confidence. The remaining substantial holdings indicate continued alignment with shareholder interests.

Key Dates

Recommendation

The insider sale by CEO Daniel Antonio Perez, executed under a pre-established 10b5-1 plan, is a routine event for executive liquidity and diversification. It does not inherently signal a change in the company's fundamental outlook or the CEO's long-term commitment, especially given his substantial remaining equity and performance unit holdings. Therefore, investors should hold their positions and monitor future company performance and broader market trends rather than reacting solely to this planned transaction.

Keywords

Hinge Health, HNGE, Daniel Antonio Perez, Insider Sale, Form 4, 10b5-1 Plan, CEO, Stock Transaction, Class A Common Stock, Class B Common Stock